ImmunityBio, Inc. IBRX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s EBITDA?
- ImmunityBio, Inc. (IBRX) reported EBITDA of -$65.41M in Q1 2026.
- How has ImmunityBio, Inc.'s EBITDA changed year-over-year?
- ImmunityBio, Inc.'s EBITDA decreased by 7.9% year-over-year, from -$60.6M to -$65.41M.
- What is the long-term trend for ImmunityBio, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s EBITDA has grown at a -6.6% compound annual growth rate (CAGR), from -$316.04M to -$240.5M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.